Search

Your search keyword '"Supasa, Piyada"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Supasa, Piyada" Remove constraint Author: "Supasa, Piyada"
208 results on '"Supasa, Piyada"'

Search Results

1. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

5. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

6. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity

7. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination

8. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

9. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

11. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

13. Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition.

14. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

15. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

16. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

17. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

18. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

19. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

20. Cooperativity and induced oligomerisation control the interaction of SARS- CoV-2 with its cellular receptor and patient-derived antibodies

21. Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency

23. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy

25. Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]

26. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

27. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

28. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses

29. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

30. Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses

31. Evaluation of T Cell Responses to Naturally Processed Variant SARS-CoV-2 Spike Antigens in Individuals Following Infection or Vaccination

35. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

37. Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2

38. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

39. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

40. Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

41. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

42. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

43. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

44. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

46. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

47. Memory cytotoxic SARS-CoV-2 spike protein-specific CD4+ T cells associate with viral control

48. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

49. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

50. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants

Catalog

Books, media, physical & digital resources